Rankings
▼
Calendar
KNSA Q2 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q2 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$27M
+250.1% YoY
Gross Profit
$17M
63.7% margin
Operating Income
-$19M
-71.8% margin
Net Income
-$20M
-74.1% margin
EPS (Diluted)
$-0.29
QoQ Revenue Growth
-16.2%
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$8M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$211M
Total Liabilities
$57M
Stockholders' Equity
$153M
Cash & Equivalents
$94M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$27M
$8M
+250.1%
Gross Profit
$17M
$4M
+306.8%
Operating Income
-$19M
-$41M
+52.2%
Net Income
-$20M
-$42M
+51.9%
Revenue Segments
Product
$27M
100%
← FY 2022
All Quarters
Q3 2022 →